Ixazomib Citrate (MLN9708)

Catalog No.S4432 Batch:S443202

Print

Technical Data

Formula

C20H23BCl2N2O9
Molecular Weight 517.12 CAS No. 1239908-20-3
Solubility (25°C)* In vitro DMSO 100 mg/mL (193.37 mM)
Ethanol 25 mg/mL (48.34 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.65mg/ml Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ixazomib Citrate (MLN9708) is a prodrug of Ixazomib (MLN2238), which is a selective, orally bioavailable inhibitor of 20S proteasome that inhibits the chymotrypsin-like proteolytic (β5) site with IC50 of 3.4 nM and Ki of 0.93 nM, respectively. Ixazomib (MLN2238) also inhibits caspase-like (β1) and trypsin-like (β2) proteolytic sites with IC50 of 31 nM and 3500 nM, respectively.
Targets
20S proteasome β5 site [1]
(Cell-free assay)		 20S proteasome β5 site [1]
(Cell-free assay)		 20S proteasome β1 site [1]
(Cell-free assay)		 20S proteasome β2 site [1]
(Cell-free assay)
0.93 nM(Ki) 3.4 nM 31 nM 3500 nM

Protocol (from reference)

Selleck's Ixazomib Citrate (MLN9708) has been cited by 11 publications

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors [ J Exp Clin Cancer Res, 2022, 41(1):249] PubMed: 35971164
NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma [ Cell Death Dis, 2022, 13(3):197] PubMed: 35236820
Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation [ Front Pharmacol, 2022, 13:1032975] PubMed: 36313330
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression [ Clin Cancer Res, 2021, 27(5):1410-1420] PubMed: 33310890
Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drug-screening effects in various human and canine cancer cell lines [ PLoS One, 2021, 16(2):e0236074] PubMed: 33544704
Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer [ Oncogene, 2019, 38(16):3047-3060] PubMed: 30617306
The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2 [ Mol Cancer Res, 2019, 17(12):2444-2456] PubMed: 31540997
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers [ Proc Natl Acad Sci U S A, 2017, 114(2):382-387] PubMed: 28028240
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma [ Mol Cancer Ther, 2017, 16(11):2375-2386] PubMed: 28878026
Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis [ Onco Targets Ther, 2017, 10:3591-3606] PubMed: 28790851

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.